FMC Partners with Corteva on Rimisoxafen, but Credit Story Unchanged

What happened

FMC announced a partnership with Corteva to expand access to its rimisoxafen dual-mode herbicide technology for corn and soybean markets across the Americas. While this deal could bolster FMC's product portfolio and competitive positioning, it does nothing to address the company's acute liquidity and covenant concerns. FMC remains deeply levered with net debt of $3.14B, operating cash flow of negative $663M in 9M 2025, and covenant headroom that required temporary relief. The partnership's financial impact is likely immaterial in the near term, as FMC's equity continues to trade as a credit-shaped turnaround dependent on working capital conversion. Until operating cash flow inflects positively without increased factoring, the core investment thesis remains broken.

Implication

The rimisoxafen deal is a positive product development but does not alter the thesis. FMC's equity is still a levered bet on Latin America collections normalizing and debt reduction. Without evidence of operating cash flow improvement in 1H 2026, the stock lacks a fundamental catalyst. The partnership may support long-term competitiveness, but near-term survival hinges on cash conversion, not product pipeline.

Thesis delta

No shift in the thesis. The partnership is a minor positive for product portfolio but does not address the dominant working-capital and leverage risks. The investment case still hinges on operating cash flow inflecting positively without increased receivables monetization, and this deal does not change that timeline or probability.